We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Not so Swiss

8 November 2004 By Robert Cyran

Europe s secondlargest biotech has seen its shares crash 30% on the failure of a drug in trials. This is far too much of a selloff leaving this highgrowth stock priced as a value one.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)